Juan-carlos C. Boluda-Hernandez

Valencia, VC, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era.

Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era.

Journal: British journal of haematology

Published: May 14, 2026

Copy-Neutral Loss of Heterozygosity in Myelofibrosis: Parallel Evaluation with Optical Genome Mapping and Single-Nucleotide Polymorphism Arrays.

Copy-Neutral Loss of Heterozygosity in Myelofibrosis: Parallel Evaluation with Optical Genome Mapping and Single-Nucleotide Polymorphism Arrays.

Journal: The Journal of molecular diagnostics : JMD

Published: September 09, 2025

Copy-Neutral Loss of Heterzygosity in Myelofibrosis: Parallel Evaluation with Optical Genome Mapping and Single-Nucleotide Polymorphism Arrays.

Copy-Neutral Loss of Heterzygosity in Myelofibrosis: Parallel Evaluation with Optical Genome Mapping and Single-Nucleotide Polymorphism Arrays.

Journal: The Journal of molecular diagnostics : JMD

Published: September 09, 2025

Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT.

Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT.

Journal: Bone marrow transplantation

Published: July 24, 2025

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study.

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study.

Journal: Blood cancer journal

Published: December 15, 2024

Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis.

Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis.

Journal: Blood

Published: June 20, 2024

Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT.

Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT.

Journal: Bone marrow transplantation

Published: June 25, 2023

Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis.

Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis.

Journal: British journal of haematology

Published: July 20, 2022

Transplantation algorithm for myelofibrosis in 2022 and beyond.

Transplantation algorithm for myelofibrosis in 2022 and beyond.

Journal: Best practice & research. Clinical haematology

Published: July 18, 2022

Impact of molecular profiling on the management of patients with myelofibrosis.

Impact of molecular profiling on the management of patients with myelofibrosis.

Journal: Cancer treatment reviews

Published: May 09, 2022

Correction: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT.

Correction: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT.

Journal: Bone marrow transplantation

Published: April 01, 2022

Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.

Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.

Journal: Leukemia research

Published: January 19, 2022

Showing 1-12 of 36

Last Updated: 09/26/2026